Outro raises $7M to scale supervised antidepressant tapering

Why it matters

Outro is financing clinician-led medication tapering as a dedicated care category, but the comparative evidence for its central hyperbolic method is still being tested. Scaling the service will depend on delivering individualized care while building a stronger evidence base.

Outro has raised $7 million across pre-seed and seed rounds to expand its supervised medication-tapering service, as co-founder and CEO Brandon Goode builds a business around a problem he encountered in psychedelic care: patients seeking new treatments were still struggling to stop antidepressants they had taken for years. The company announced the funding on October 8th, alongside plans to grow its clinician network, apply AI to clinical workflows and extend its approach to other drug classes.

Goode's route into deprescribing ran through Novo Nordisk and Field Trip Health, where he worked in market access and strategic partnerships. In a 2023 interview, he said his work in interventional psychiatry brought him into contact with people who wanted to stop taking antidepressants but had difficulty doing so. The problem, as Goode described it, was easy to miss in a field focused on developing or offering new therapies: there was little organized support for getting off existing medication.

Outro's co-founder Mark Horowitz brings the clinical research behind the company's approach. Horowitz has described how severe withdrawal after taking an antidepressant for 15 years led him to study safer ways to stop. The company's account of its founding traces that experience to his research into hyperbolic tapering, in which dose reductions become progressively smaller as a patient approaches zero.

A clinic built around the taper

The funding announcement names Listen Ventures, Cake Ventures, LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures among the backers. The company did not specify the lead investor, how the $7 million is divided between the two rounds, the valuation or the rounds' closing dates.

Outro is selling clinician time and coordination, not a stand-alone tapering app. Its service combines individualized dose plans, symptom monitoring, appointments and access to compounded medication. The funding announcement says the money will support the clinician network, AI-assisted workflows, expansion into additional medication classes and university and advocacy partnerships. The antidepressant program is available in 14 states, according to the company.

The day-to-day work behind that model came into view in Business Insider's account of psychiatric nurse practitioner Kristen Massingill. She told the outlet she has about 100 patients and spends up to an hour on an initial evaluation, with follow-ups typically lasting about 30 minutes. Her patients' plans can involve holding a dose, slowing reductions or switching formulations as symptoms and circumstances change.

Some patients open capsules and weigh their contents on jewelry scales to make smaller reductions; others use liquid medication or specially compounded tablets. Massingill said patients' preferences and routines shape which method they use. She also said Outro turns away some people when tapering is not appropriate. That boundary is central to a service whose pitch depends on individual clinical judgment, rather than a single schedule that patients follow on their own.

The clinical question behind Outro's business remains under study. Hyperbolic tapering has been proposed as an alternative to fixed-size dose reductions, but a 2026 BMJ Open trial protocol says randomized evidence directly comparing linear and hyperbolic approaches is lacking. The paper lays out a trial intended to compare the methods; it is a protocol, not a report of results. Outro's service is built around the approach, while definitive comparative evidence is still being pursued.

From a founder's thesis to a larger market

Goode's bet is that stopping medication can become a defined part of care rather than a task patients and their regular prescribers handle without dedicated time. In the funding announcement, he described the goal as building an "off-ramp" to match the support patients receive when starting medication. The company plans to take its current approach beyond antidepressants, though the announcement does not name the next drug classes or set a timetable.

That expansion gives the new capital a practical purpose: more clinicians, more medication formulations and a service model that may need to adapt to different drugs and patients. It also puts the company in a field where the care is labor-intensive and where its clinical claims will need evidence beyond patient experience and the company's own marketing. For now, Outro's disclosed scale is a 14-state program and Massingill's roughly 100-patient caseload; the funding announcement supplies no companywide patient count, revenue or growth figures.

The opportunity rests on making deprescribing a service people can access and clinicians can deliver with enough time for careful adjustment. Goode has raised capital to build that infrastructure. Whether it can expand without losing the individualized attention that Massingill describes will be the operating test.